Dermira, Inc.

Dermira, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for chronic skin conditions, focusing on improving patient outcomes through advanced therapeutic solutions. Dermira, Inc. operates in the biopharmaceutical sector, focusing on the development of therapies for chronic skin conditions.

Founded in 2010 and headquartered in Menlo Park, US, the company was established by Luis Peña. It has raised a total of USD 1,100. 00 mn through various funding rounds. The most recent funding round was a Trade Sale on October 2, 2014, which raised USD 1,100.

00 mn, with Eli Lilly and Company as a notable investor. Dermira specializes in the development and commercialization of pharmaceutical products aimed at treating chronic skin conditions. Their core offerings include medications designed to alleviate symptoms of various dermatological disorders, enhancing the quality of life for patients. The company targets healthcare professionals, hospitals, and pharmacies, ensuring the availability of its products in key markets across North America, Europe, and Asia.

In 2018, Dermira reported a revenue of USD 42. 34 mn, with an EBITDA of USD -207. 19 mn, indicating a focus on substantial investment in research and development for future growth. Dermira plans to leverage recent funding to support the launch of new products targeting chronic skin conditions, with specific product releases expected in the coming years.

The company also aims to expand into new geographical regions, particularly focusing on markets in Europe and Asia by 2025. The USD 1,100. 00 mn raised in its latest funding round will be crucial in advancing these initiatives and enhancing its product pipeline.